TD Cowen raises Grail stock price target to $180 on FDA outlook
TD Cowen raised its price target for Grail (NASDAQ:GRAL) to $180 from $88, citing increased FDA approval prospects and CMS reimbursement confidence. The stock has surged 186% in six months. Analysts highlight high valuation multiples and regulatory developments as key factors. Grail develops early cancer detection tests.
How this was made
The 30-second read
Why it matters
The upgrades suggest renewed confidence but may not translate into immediate price moves given recent strong performance.
Market read
Analyst upgrades may sustain bullish bias but limited upside given recent gains.
What to watch
Potential reimbursement challenges and competition from other liquid biopsy platforms.
Background
Analyst firms updated price targets after a favorable FDA advisory committee meeting for Grail's Galleri test.
Ticker impact
TD Cowen raised its price target for Grail to $180, citing improved FDA outlook and higher CMS coverage probability.
likely upward pressure as the market digests the higher target
The new target reflects optimism but the stock is already up 60% YTD, limiting upside.
Market effects
May lift sentiment for other early‑cancer detection firms.
Limited to US biotech sector.
Minor, confined to niche oncology diagnostics market.
Counterpoint
The stock may be overvalued given its high multiple; price target hikes could be premature.
Key entities
- analystTD Cowen
Raised Grail price target to $180.
- analystCanaccord Genuity
Raised price target to $150.
- analystMizuho
Raised price target to $100.
